De Pinte, Belgium

Tinneke Denayer

USPTO Granted Patents = 8 


 

Average Co-Inventor Count = 9.3

ph-index = 4

Forward Citations = 65(Granted Patents)


Location History:

  • Ghent, BE (2014)
  • De Pinte, BE (2016 - 2024)

Company Filing History:


Years Active: 2014-2024

Loading Chart...
Loading Chart...
Loading Chart...
8 patents (USPTO):Explore Patents

As an AI assistant specializing in innovations, inventions, inventors, patent attorneys, assignees, and patents, I can provide you with an article about the inventor Tinneke Denayer.

Title: Innovator Tinneke Denayer: Pioneering Solutions in Immunoglobulin Single Variable Domain Research

Introduction: Tinneke Denayer, a visionary inventor based in De Pinte, BE, has made significant contributions to the field of immunoglobulin single variable domain research. With a total of 8 patents to his name, Denayer has been at the forefront of developing techniques for predicting, detecting, and reducing aspecific protein interference in assays involving ISVs.

Latest Patents: Denayer's most recent patent focuses on innovative assays designed to predict and mitigate protein interference in ISVs. These assays enable the identification of ISVs that are less prone to interference, as well as methods for modifying and improving ISVs to minimize unwanted signals. His groundbreaking work has paved the way for enhanced accuracy and reliability in immunoassays.

Career Highlights: Denayer's expertise has been instrumental in renowned companies such as Ablynx N.V. and Sanofi, where he has applied his inventive concepts to drive advancements in biotechnology. His strategic approach to ISV research has garnered recognition within the industry for its profound impact on assay development.

Collaborations: Throughout his career, Denayer has collaborated closely with esteemed colleagues such as Gerald Beste and Guy Hermans. Together, they have pushed the boundaries of ISV technology and spearheaded collaborative efforts to revolutionize protein interference detection methodologies.

Conclusion: Tinneke Denayer's inventive spirit and dedication to advancing ISV research have solidified his reputation as a trailblazer in the biotechnology landscape. His pioneering patents and collaborative endeavors continue to shape the future of immunoglobulin research, inspiring innovation across the scientific community.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…